The transaction, which values Antares at $960 million, demonstrates Halozyme's commitment to drug delivery In a deal that will strengthen its emphasis on the delivery of drugs, Halozyme Therapeutics Inc. offered to acquire specialised biopharmaceutical business Antares Pharma Inc. for roughly 1 billion dollars. Halozyme released a Statement saying that it would pay $5.60 per share in cash for Antares, pricing the company at $960 million. The Wall Street Journal reported earlier in the day that the two corporations were close to reaching an agreement. Antares' stock rose over 50% in premarket trading on Wednesday. They were trading at $3.74 on Tuesday, giving Antares a market capitalization of $640 million. Antares, based in Ewing, New Jersey, specialises in injectable medications and offers a range of testosterone replacement therapy Based in San Diego Halozyme has a market capitalization of $5.7 billion. The transaction is the first significant step in Halozyme's plan to expand through merger or acquisition, which was prompted by the failure of a clinical trial for a pancreatic anticancer therapy in 2019. Enhanze, a drug-delivery product developed by Halozyme is an enzyme that allows hours-long intravenous drug treatments to be administered in minutes. Pfizer Inc. and Bristol-Myers Squibb Co. are among the companies that have licenced the technology. Antares' acquisition would allow the firm to expand its therapeutics network and diversify its offerings by adding speciality pharmaceuticals. While medicine is usually one of the busiest industries for mergers and acquisitions, activity has slowed dramatically this year. As per Dealogic, approximately $72 billion in medical mergers have been reported so far this year, down from $162 billion at the same time last year. Resulting from market instability, greater regulatory inspection, and concern emanating from Russia's incursion of Ukraine, global deal volumes across all sectors are down around 28% from last year.
Sick and tired of always wondering if you are being asked to pay the right price for your APIs? This empowers you with the answers you need to make the right decisions in the Global API market.
Chemxpert Database is one of the biggest and most comprehensive directories of pharma and chemicals, manufacturers, suppliers and information. Provided with current information on prices, demand and transactions, it gives you instant feedback on whether you are buying what is right and at the right time.
Start using market intelligence today and allow yourself to be in control in the API market.
Check it out today and make more informed sourcing decisions! Learn More!